Trial · NCT04003155
Adverse events145
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 145
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | COVID-19 | Infections and infestations | Double-blind Period: Placebo | 0 | 175 | 0 |
| other | COVID-19 | Infections and infestations | Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg | 9 | 174 | 9 |
| other | COVID-19 | Infections and infestations | Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg | 11 | 173 | 11 |
| other | COVID-19 | Infections and infestations | Double-blind Period: Placebo/Extension Period: Fezolinetant 30 mg | 4 | 76 | 4 |
| other | COVID-19 | Infections and infestations | Double-blind Period: Placebo/Extension Period: Fezolinetant 45 mg | 6 | 76 | 6 |
| other | Urinary tract infection | Infections and infestations | Double-blind Period: Placebo | 3 | 175 | 3 |
| other | Urinary tract infection | Infections and infestations | Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg | 3 | 174 | 6 |
| other | Urinary tract infection | Infections and infestations | Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg | 9 | 173 | 9 |
| other | Urinary tract infection | Infections and infestations | Double-blind Period: Placebo/Extension Period: Fezolinetant 30 mg | 2 | 76 | 2 |
| other | Urinary tract infection | Infections and infestations | Double-blind Period: Placebo/Extension Period: Fezolinetant 45 mg | 1 | 76 | 2 |
| other | Alanine aminotransferase increased | Investigations | Double-blind Period: Placebo | 4 | 175 | 4 |
| other | Alanine aminotransferase increased | Investigations | Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg | 8 | 174 | 9 |
| other | Alanine aminotransferase increased | Investigations | Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg | 10 | 173 | 13 |
| other | Alanine aminotransferase increased | Investigations | Double-blind Period: Placebo/Extension Period: Fezolinetant 30 mg | 2 | 76 | 2 |
| other | Alanine aminotransferase increased | Investigations | Double-blind Period: Placebo/Extension Period: Fezolinetant 45 mg | 2 | 76 | 2 |
| other | Blood alkaline phosphatase increased | Investigations | Double-blind Period: Placebo | 6 | 175 | 6 |
| other | Blood alkaline phosphatase increased | Investigations | Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg | 6 | 174 | 6 |
| other | Blood alkaline phosphatase increased | Investigations | Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg | 5 | 173 | 8 |
| other | Blood alkaline phosphatase increased | Investigations | Double-blind Period: Placebo/Extension Period: Fezolinetant 30 mg | 5 | 76 | 11 |
| other | Blood alkaline phosphatase increased | Investigations | Double-blind Period: Placebo/Extension Period: Fezolinetant 45 mg | 1 | 76 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04003155/events